Aurinia Pharmaceuticals Inc. (TSX:AUP), a Canadian biopharma stock, rocketed higher after announcing results from its AURORA Phase 3 trial of voclosporin
Statistically-significant Phase 3 trial results sent a Canadian biopharma stock surging Thursday. Here’s some small stocks making big moves on Thursday, December 5, 2019 (as of 4 pm EST):
Aurinia Pharmaceuticals Inc. (TSX:AUP), a Canadian biopharma stock, powered 78% higher to $19.75 on Thursday after announcing results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate and low-dose corticosteroids, in the treatment of lupus nephritis, which the Company said achieved “statistically significant improvements.” Aurinia added that it plans to file an NDA submission to the FDA during the first half of 2020.
As well, shares of Zenabis Global Inc. (TSX:ZENA) slipped 3% to $0.185 as the Canadian cannabis company said its cultivation output in October 2019 increased 71% over the September yield, totaling 3,586 kg of dried cannabis, although this fell slightly short of its forecast of 3,758 kg.
Select Sands Corp. (TSXV:SNS), meanwhile, reported that its wholly-owned subsidiary, Select Sands America Corp., has entered into a three-year supply agreement with a large-cap exploration and production company in The Eagle Ford Basin. Select Sands stock moved up 100% to $0.03 following the announcement.
Finally, QMX Gold Corporation (TSXV:QMX) shares rose 33% to $0.06 after the junior explorer announced the first results from its Fall drilling campaign on the Bonnefond deposit in Quebec, which included 10.66 g/t gold over 11.2 metres.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Aurinia Pharmaceuticals Inc. (TSX:AUP), a Canadian biopharma stock, powered 78% higher to $19.75 on Thursday after announcing results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate and low-dose corticosteroids, in the treatment of lupus nephritis, which the Company said achieved “statistically significant improvements.” Aurinia added that it plans to file an NDA submission to the FDA during the first half of 2020.
